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Abstract
Background: Undifferentiated febrile illness (UFI) includes typhoid and typhus fevers and generally designates fever
without any localizing signs. UFI is a great therapeutic challenge in countries like Nepal because of the lack of available
point-of-care, rapid diagnostic tests. Often patients are empirically treated as presumed enteric fever. Due to the
development of high-level resistance to traditionally used fluoroquinolones against enteric fever, azithromycin is now
commonly used to treat enteric fever/UFI. The re-emergence of susceptibility of Salmonella typhi to co-trimoxazole
makes it a promising oral treatment for UFIs in general. We present a protocol of a randomized controlled trial of
azithromycin versus co-trimoxazole for the treatment of UFI.
Methods/design: This is a parallel-group, double-blind, 1:1, randomized controlled trial of co-trimoxazole versus
azithromycin for the treatment of UFI in Nepal. Participants will be patients aged 2 to 65 years, presenting with fever
without clear focus for at least 4 days, complying with other study criteria and willing to provide written informed consent.
Patients will be randomized either to azithromycin 20 mg/kg/day (maximum 1000 mg/day) in a single daily dose and an
identical placebo or co-trimoxazole 60 mg/kg/day (maximum 3000 mg/day) in two divided doses for 7 days. Patients will
be followed up with twice-daily telephone calls for 7 days or for at least 48 h after they become afebrile, whichever is later;
by home visits on days 2 and 4 of treatment; and by hospital visits on days 7, 14, 28 and 63. The endpoints will be fever
clearance time, treatment failure, time to treatment failure, and adverse events. The estimated sample size is 330. The
primary analysis population will be all the randomized population and subanalysis will be repeated on patients with blood
culture-confirmed enteric fever and culture-negative patients.
Discussion: Both azithromycin and co-trimoxazole are available in Nepal and are extensively used in the treatment of UFI.
Therefore, it is important to know the better orally administered antimicrobial to treat enteric fever and other UFIs
especially against the background of fluoroquinolone-resistant enteric fever.
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Background
The difficulty in determining the etiology of undiffer-
entiated febrile illness (UFI), which designates fever
without localizing signs, and the emergence of resist-
ance to commonly used antimicrobials means that the
appropriate management of UFIs is an ongoing clin-
ical challenge. The non-specific clinical presentation
of many infections that cause UFI makes it difficult
to distinguish one cause from another based on clin-
ical history, physical examination and basic initial
laboratory investigations alone [1].
UFIs in industrialized countries are often attributed to a
viral syndrome but in the developing world UFI may be
commonly caused by enteric fever, rickettsial illness,
malaria, dengue, chikungunya, etc. depending upon local
epidemiology. The common causes of UFI in Kathmandu,
Nepal includes enteric (typhoid and paratyphoid) fever
and murine and scrub typhus [2, 3]. The pooled data of
2092 patients with UFI enrolled in four clinical trials
conducted in the same study setting showed culture
positivity in 885 (41%) patients for either Salmonella typhi
or Salmonella paratyphi [4]. A study conducted in serum
samples of a proportion of randomly selected patients
from one of these trials showed serological evidence for
acute murine typhus in 17% (n = 21/125) of patients [3].
Additionally, the spotted fever group rickettsioses, Q fever,
leptospirosis, hantavirus infection, brucellosis and dengue
may also cause UFI in Nepal [3].
There is no reliable point-of-care diagnostic test to de-
termine rickettsial infections, self-remitting viral infections
and many other febrile illnesses. Blood culture which is
the “gold standard” test to determine enteric fever takes
from 3 to 7 days. Therefore, treatment has to be guided by
the clinical characteristics of the syndrome that the patient
presents with and knowledge of local epidemiology of
these common diseases. We have observed that most
patients with UFI in Nepal are empirically treated as
presumed enteric fever (in a high-incidence area) or as
fever without a focus requiring antimicrobials (in a rela-
tively low-incidence area). Our working definition for UFI
is fever of ≥ 38.0 °C for at least 4 days’ duration with no
clear-cut focus of infection such as productive cough,
diarrhea, urinary symptoms, or any signs of neck stiffness
or localized abscess. We exclude the patients with a
fever duration of less than 4 days and a recorded
temperature < 38 °C in an attempt to exclude the
majority of patients with probable self-remitting viral
infection. An appropriate antimicrobial, in addition to
the supportive treatment, needs to be administered
empirically to these patients in a setting where a large
proportion of these UFIs is known to be caused by
bacterial and rickettsial illnesses. Orally administered
azithromycin is commonly used to treat UFI in Nepal
and remains effective against enteric fever [5–7].
Fluoroquinolones cannot now be used to treat enteric
fever in Nepal and South Asia as high levels of resistance
have emerged against them within the S. typhi popula-
tion [8–10]. This is further supported by endemic preva-
lence of a fluoroquinolone-resistant subclade of H58 S.
typhi in Nepal [11]. This highlights the need for alterna-
tive antimicrobial treatments and to consider using the
first-line drugs chloramphenicol, amoxicillin and co-tri-
moxazole for enteric fever [12]. These drugs are the
“low-hanging fruits” in UFI treatment as suggested by by
O’Neill’s [13] recent review on the global burden of anti-
microbial resistance.
Co-trimoxazole has been commonly used in the past
for the treatment of enteric fever [14, 15]. However, re-
sistance to co-trimoxazole emerged two decades ago,
but has subsequently largely disappeared and nearly all
S. typhi and S. paratyphi A isolates from Nepal are now
susceptible to this drug [9, 16–18]. Anecdotal reports
claim that it performs well clinically for treating UFI in
Nepal and it is a widely available at low cost. Its effect-
iveness against enteric fever is corroborated by a recent
case report [19] and demonstrable low co-trimoxazole
Minimum Inhibitory Concentrations (MICs) for S. typhi
and S. paratyphi A [17, 20].
Both azithromycin and co-trimoxazole are available
in Nepal and are extensively used in the treatment of
UFI. Therefore, it is important to know the better
oral option to treat enteric fever and other febrile ill-
nesses. This would also aid in securing an alternative
oral treatment in case resistance to azithromycin
emerges.
Methods/design
Purpose/hypothesis
We hypothesize that azithromycin has a wider spectrum
of activity against the major causes of UFI in Nepal (S.
typhi and S. paratyphi; scrub and murine typhus) than
co-trimoxazole and will, therefore, be associated with
more rapid fever clearance times (FCTs) and less treat-
ment failure.
Objectives
Primary objective
To determine whether azithromycin has a faster FCT
than co-trimoxazole for the treatment of UFI in
Nepal.
Secondary objectives
 To determine whether azithromycin is superior to
co-trimoxazole for the treatment of blood-culture-
negative UFI
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 To determine whether azithromycin is similarly
efficacious as co-trimoxazole for the treatment of
blood-culture-positive enteric fever
 To assess the causes of UFI in blood-culture-negative
patients
Study design
This is a parallel-group, double-blind, 1:1, randomized
controlled phase-III trial of azithromycin versus co-
trimoxazole for the treatment of UFI in Nepal.
Study setting
The study will be conducted at Patan Hospital, the
teaching hospital of Patan Academy of Health
Sciences (PAHS), Lalitpur, Nepal. Patan Hospital is a
tertiary-care center located in urban Lalitpur, with a
large number of patients visiting the hospital for
clinical care from both rural and urban areas of
Kathmandu Valley and also a large number of patients
referred from different parts of Nepal.
Participants, interventions and outcomes
Participants will be the patients presenting with febrile
illness to the emergency room and outpatient clinics of
Patan Hospital and they will be recruited from the Fever
Study Clinic at the hospital. The flow chart below
illustrates the study plan for recruitment, intervention,
outcome and follow-ups (see Fig. 1).
Eligibility criteria
Inclusion criteria
1. Fever of ≥ 38.0 °C and for at least 4 days without a
clear-cut focus of infection (as assessed by history
and physical examination)
2. Older than 2 years and below 65 years of age
3. Able to take tablets orally
4. Residing in Kathmandu Valley
5. Able to attend follow-up visits
6. Can be contacted by telephone/mobile phone
24 h a day
7. Written informed consent to participate in the study
including assent for minors in addition to parental
consent
Exclusion criteria
1. Fever for more than 14 days
2. Pregnancy
3. Obtundation
4. Shock
5. Visible jaundice
6. Presence of signs of gastrointestinal bleeding
7. History of hypersensitivity to either of the trial drugs
8. Patient requiring intravenously administered
antimicrobials or hospital admission for any reason
as decided by the study physician and the attending
physician
9. The study physician considers either of the trial
drugs to be contraindicated for any reason (e.g.,
drug interactions, as described below)
10.Any patient fulfilling the inclusion criteria but
already taking antimicrobials and responding
clinically to the treatment as judged by the study
physician
Interventions
Patient will be randomized to one of the two treatment
groups:
 Group A: azithromycin tablets 20 mg/kg/day as a
single daily dose for 7 days (maximum dose
1000 mg/day)
 Group B: co-trimoxazole tablets (trimethoprim
10 mg/kg + sulfamethoxazole 50 mg/kg) in two
divided doses everyday for 7 days (maximum
3000 mg/day)
The drug doses will be adjusted according to the
weight of individual patients. An additional Excel sheet
illustrates this in more detail (see Additional file 1)
Description of study interventions
Azithromycin
Azithromycin is a macrolide antimicrobial derived from
erythromycin, but has a methyl-substituted nitrogen in
its 15-member lactone ring. It is, therefore, an azalide
antimicrobial. It acts by inhibiting ribonucleic acid
(RNA)-dependent protein synthesis by binding to the re-
ceptor at the bacterial 50S ribosomal subunit [21]. Azi-
thromycin is available in capsules for oral use as
azithromycin dihydrate, in film-coated tablets, as a pow-
der for oral suspension and as a powder to prepare an
intravenous solution.
Co-trimoxazole
Co-trimoxazole is a combination of two antimicrobial
agents, trimethoprim and sulfamethoxazole, in the
ratio 1:5.
Sulfamethoxazole is a sulfonamide, a structural analogue
of para-aminobenzoic acid (PABA). It competes with
PABA to bind to dihydropteroate synthetase and inhibit
the conversion of PABA and dihydropteroate diphosphate
to dihydrofolic acid, or dihydrofolate. This action inhibits
the production of dihydrofolate intermediates and inter-
feres with the normal bacterial synthesis of folic acid
(folate) and deoxyribonucleic acid (DNA) synthesis [22].
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Trimethoprim is a 2, 4-diamino-5-(3′,4′,5′-tri-
methoxybenzyl) pyrimidine. It has powerful inhibition
activity on bacterial dihydrofolate reductase, which is
the enzymatic step after the step in folic acid synthe-
sis that is blocked by sulfonamides [23]. It thus inter-
feres with the conversion of dihydrofolate to
tetrahydrofolate, the precursor of folinic acid and ul-
timately of purine and DNA synthesis. The sequential
blockage of the same biosynthetic pathway by sulfa-
methoxazole and trimethoprim results in a high de-
gree of synergistic activity against a wide spectrum of
microorganisms [23].
Co-trimoxazole is available as oral tablets, oral cap-
sules and an oral suspension in different strengths
combining trimethoprim and sulfamethoxazole in the
ratio 1:5.
Concomitant medications
The following medications should be avoided for
patients in each treatment group:
Azithromycin
 Aluminum and magnesium antacids delay
absorption and reduce the peak serum
concentration and should be avoided with
azithromycin
Fig. 1 Descriptive flow chart of study plan
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Co-trimoxazole
 Angiotensin-converting enzyme (ACE) inhibitors
and angiotensin-receptor blockers have an additive
hyperkalemic effect when used with co-trimoxazole
 The hypoglycemic action of sulfonylureas and
thiazolidinediones is enhanced when concomitantly
used with co-trimoxazole
 Co-trimoxazole interacts with warfarin through the
CYP450 and CYP2C9 systems, increasing the risk of
bleeding
 Concomitant administration of co-trimoxazole and
methotrexate results in decreased renal clearance of
free methotrexate and may result in severe
pancytopenia
 Active levels of phenytoin may be increased
markedly by co-trimoxazole, especially in older
patients
 Concomitant use may increase the serum level of
other drugs like rifampicin, dapsone, amiodarone,
digitalis, amantadine, pyrimethamine, cyclosporine,
fluoxetine, montelucast, zafirlukast, paclitaxel
Outcomes
Primary endpoints
Fever clearance time (FCT): this will be the time from
the first dose of a study drug until a temperature of ≤
37 · 5 °C has been achieved for at least 48 h.
Secondary endpoints
1. Treatment failure, defined as the occurrence of at
least one of the following events
(a)Fever failure, defined by FCT above 7 days
(168 h) post treatment initiation
(b)Requirement for rescue treatment as judged by
the study physician and the attending physician
(c)Blood-culture-0positive for S. typhi or an S.
paratyphi on day 7 of treatment regardless of
fever (microbiological failure)
(d)Culture-confirmed or syndromic enteric fever
relapse within 28 days of initiation of treatment
(e)The development of any complication (e.g.,
clinically significant bleeding, fall in the Glasgow
Coma Scale score, perforation of the
gastrointestinal tract) or need for hospital
admission within 28 days after the initiation of
treatment
2. Time to treatment failure, defined as the time from
the first dose of treatment until the date of the
earliest failure event
3. Adverse events (grade-3/4/5 adverse events, serious
adverse events, adverse events of any grade leading
to modification of study-drug dose or interruption/
early discontinuation)
Rescue treatment and post-trial treatment
Patients who meet the criteria for treatment failure as
defined above will be administered rescue treatment.
Rescue treatment will be as follows: treatment failures
with a positive blood culture for S. typhi and S. paraty-
phi at the time of enrollment will be treated with
injected ceftriaxone 60 mg/kg once daily (maximum
dose 2 g/day) for 7 days and culture-negative individuals
will be treated with injected ceftriaxone 60 mg/kg once
daily (maximum dose 2 g/day) and doxycycline tablet
4 mg/kg/day in two divided doses (maximum 200 mg/
day) for 7 days.
Patients who develop adverse events (grade-3/4/5 ad-
verse events, serious adverse events, adverse events of
any grade leading to modification of study drug dose or
interruption/early discontinuation) will stop receiving
the study drug and be given rescue treatment as above.
If treatment failure occurs in patients who are found
to be infected with organisms other than S. typhi or S.
paratyphi the choice of the rescue treatment will be de-
termined after full clinical assessment and consideration
of the laboratory results by the study physician in con-
sultation with the attending physician.
Patients requiring hospital admission for any reason,
as decided by the study physician and the attending
physician, will be admitted to the hospital and treated as
per standard clinical care. They will remain in the study
with all outcomes recorded. Patients will be treated ac-
cording to standard clinical care for all adverse events
and upon completion of the study as required.
Participant timeline
Identification of participants, consent and enrollment
Patients aged 2 years and older and under 65 years who
present at the emergency room and outpatient clinics of
Patan Hospital, who have a temperature of ≥ 38.0 °C and
a documented or self-reported history of fever for at
least 4 days and less than 14 days, without a focus of in-
fection (as assessed by history and physical examin-
ation), will be identified by clinicians in the hospital and
will be referred to the study clinic. At the study clinic,
the study physician will screen the patients by study
criteria for enrollment into the study.
The study physician will obtain written informed con-
sent from all the study participants aged over 18 years of
age before enrollment in the study. For patients aged 12
to 18 years of age, written informed consent will be ob-
tained from a legal guardian in addition to an assent
from the participant. Written informed consent will be
obtained from legal guardians for patients under 12 years
of age. In case of legal guardians/patients who cannot
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read, an impartial witness, who is not a part of the re-
search team (if the patient is not accompanied by some-
one who is literate, this can be one of the staff members
from the hospital medical record office), will sign to
confirm that the Informed Consent Form was accurately
read to the patient and that the patient agreed to partici-
pate. The study physician will also approach partici-
pants/legal guardians for an additional consent for
storage of blood and urine samples for future studies.
All study participants will receive a copy of the signed
Informed Consent Form.
After signing an informed consent, patient will be
assigned a study number (this is the same as the
randomization number) and will be enrolled into the
study. The study staff will ensure that the participants’
anonymity is maintained. Participants will be identified
only by their initials and a study number. All documents
will be stored securely and will be accessible to trial staff
and authorized personnel only.
Screening failure
Patients who do not meet the inclusion/exclusion cri-
teria for the study will be informed that they cannot par-
ticipate in the trial and will be treated according to the
standard protocol of clinical care including antimicrobial
therapy. Details of all patients who are approached for
participation in the trial will be noted in the “Screening
Case Report Form (CRF).”
Baseline procedures
After signing the informed consent, but prior to enroll-
ment, patients will undergo:
 Full history and clinical examination including
documentation of clinical manifestations according
to a standard proforma
 Complete blood count (CBC): hematocrit, total
white cell count, differential count, platelet count
(blood volume 1 ml)
 Biochemistry: blood glucose, creatinine, serum
glutamine oxaloacetate transaminase (SGOT), serum
glutamine pyruvate transaminase (SGPT) (blood
volume 1 ml)
 Urine for routine examination and storage
 Blood culture: blood volume 5–8 ml for patients
aged at least 14 years of age and 3 ml for patients
below 14 years of age
 EDTA-preserved blood will be separated into plasma
and a cell pellet and stored for future testing (3 ml)
 Stool culture: collect in readymade tubes with Cary
Blair medium
The causes of fever will be investigated in all pa-
tients according to routine clinical practice norms.
Patients will be screened by other investigations for
any specific diseases prior to enrollment in case of
strong clinical suspicion during history taking and
clinical examination; for example, a chest X-ray for
patients with cough and/or pleuritic chest pain to
rule out lower respiratory tract infections, urine rou-
tine examination for urinary symptoms, CBC to
screen for leukocytosis if any symptom are suggestive
of a specific focus of infection, etc.
Study duration
For each enrolled patient, study duration will be from
day 0 (day of enrollment) until day 63 (day of final
follow-up). The schedule for intervention and assess-
ment during the study period is illustrated in a Standard
Protocol Items: Recommendation for Interventional
Trials (SPIRIT) Figure, see Fig. 2.
Day 0 – day 7
Patients will be contacted by telephone calls twice daily
by study nurses between 06:30 and 07:30 and 18:30 and
19:30 to record drug doses and administration times,
oral temperatures and time of temperature readings,
symptoms and potential adverse effects.
Each patient will be given a digital thermometer and
the “Patient Copy of Temperature and Medication
Record” page of the CRF and will be asked to record
their oral temperature and amount of paracetamol
intake at 06:00 and 18:00 and during any febrile episode
between each day; and indicate study-drug intake with a
tick mark. “Hospital Copy of Temperature and Medica-
tion Record” will be verified with the “Patient Copy of
Temperature and Medication Record” when patients
follow-up on day 7. A symptom checklist will also be
completed daily and recorded to assess complications or
adverse events.
Patient will be followed up by home visits by commu-
nity medical auxiliaries (CMAs) on day 2 and day 4 to
monitor patients’ vital signs, keep track of patients in
case they are lost to follow-up and maintain patient
rapport.
Follow-up: day 7 (±1 day)
Patients will be examined by the study physician at study
clinic. The following tests will be performed:
 Blood will be collected in a 10-ml syringe for CBC,
random blood glucose (RBG), SGPT, SGOT, creatinine,
culture and plasma storage for patients whose blood
culture is positive for S. typhi or S. paratyphi A at the
day of enrollment
 Blood will be collected in a 5-ml syringe for CBC,
RBG, GPT, GOT, creatinine and plasma storage for
patients who are blood-culture-negative on the day
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of enrollment. If culture-negative patients have not
cleared their fever on day 7, a blood culture will also
be performed
 Stool culture (collected in readymade tubes with
Cary Blair medium) for patients whose blood is
culture-positive for S. typhi or S. paratyphi A on the
day of enrollment
Day 8 – day 10
For the patients who are febrile on days 6/7, daily tele-
phone calls and a record of oral temperature and symp-
toms will be continued in the same manner.
Follow-ups: day 14 (±2 days), day 28 (±3 days), day 63
(±3 days)
Patients will be reexamined by the study physician
at the study clinic. The following tests will be
performed:
 Blood will be collected in a 3-ml syringe for plasma
storage
 Stool culture (collected in readymade tubes with
Cary Blair medium) for patients whose blood culture
is positive for S. typhi or S. paratyphi A on the day
of enrollment
Further diagnostic tests
Further diagnostic tests for UFI, including enzyme-linked
immunosorbent assay (ELISA) and polymerase chain reac-
tion (PCR), will be performed on archived paired samples of
blood collected on days 1 and 28 ± 3 days for scrub typhus,
murine typhus, spotted fever group rickettsioses, Q fever,
leptospirosis, hantavirus infection, brucellosis and dengue
on patients whose initial blood culture shows no growth for
S. typhi or S. paratyhi. These tests will be conducted in the
future to determine the causes of UFI and will not influence
present clinical care. It will be explained to patients that if
any additional tests performed on their blood samples are
positive, they will be informed once the results are available.
Discontinuation of treatment and participation
If a patient or patient representative, who has given
consent on their behalf, opts to discontinue the trial
Fig. 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Figure: summary of enrollment, intervention and assessment. X
Activities at hospital or home visits, Activities that will be recorded over a telephone call, (X) Will be done only for culture-positive patients at
day 0 or those with persistent fever/symptoms, X* Will be done retrospectively if blood culture shows no growth after 7 days
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treatment for any reason, they are encouraged to follow
the study procedures and attend follow-ups as far as
possible instead of completely withdrawing from the
trial. If they do not wish to remain on trial follow-up,
however, their decision will be respected and the pa-
tients will be completely withdrawn from the trial. The
reason for the patient withdrawing should be ascertained
wherever possible. Prior to withdrawing from the trial,
the patient will be invited to have assessments per-
formed as appropriate for the final visit although they
would be at liberty to refuse any or all individual compo-
nents of the assessment.
In addition, the investigator may decide to stop the
study intervention if they feel that it is not in the best
interest of the patient. Patients will be followed as per
protocol.
Sample size
The target sample size for this trial is 330 participants
(165 per study group). This sample size is based on the
sample size justification for 300 patients with an add-
itional allowance of 10% to account for potential loss to
follow-up and other deviations from the protocol
assumptions.
Sample size justification
We assumed a Weibull distribution for the FCT in each
arm and a median FCT in the azithromycin arm of
1.12 days in those with culture-negative UFI and
2.78 days in those with culture-positive UFI. This corre-
sponds to the observed values for gatifloxacin in culture-
negative patients and ceftriaxone for culture-positive pa-
tients in our previous trial [9]. The shape parameter of
the Weibull distribution was assumed to be 0.75 for
culture-negative patients and 1.5 in culture-positive
patients. This estimation is conservative (i.e., implies
slightly more variability) compared to the observed FCT
distributions in the previous three typhoid trials con-
ducted in Nepal [8, 20, 24]. Regarding the effect size, we
assume that co-trimoxazole is associated with a two-fold
slower FCT in culture-negative patients and the same
FCT as azithromycin in culture-positive patients. Of
note, for the culture-negative patients, a 2.26-fold slower
FCT was observed in the ceftriaxone arm compared to
gatifloxacin in our previous trial [9]. Finally, we assumed
that the proportion of patients with culture-confirmed
typhoid is between one third and one half of the total
population. Based on these assumptions and an assumed
twice-daily temperature monitoring leading to an
interval-censored FCT, power for varying samples sizes
was estimated based on simulation. Results for the
chosen total sample size of n = 300 (150 per treatment
group) are reported below (see Table 1) and provide a
power of ≥ 80% for the overall comparison with a two-
sided 5% significance level.
Assignment of interventions
Randomization and blinding
All patients enrolled into the study will be randomly
assigned in a 1:1 ratio to either co-trimoxazole or
azithromycin according to a computer-generated
randomization list, with randomization in variable block
sizes of 4 and 6 without stratification. The randomization
list will specify the assignment of each unique study num-
ber to the respective randomized treatment arm.
The study drugs have been manufactured by Lomus
Pharmaceuticals, Kathmandu, Nepal. The tablets have
been manufactured as follows: co-trimoxazole tablets
of dose 1200 mg, 600 mg and 300 mg and 150 mg,
azithromycin tablets of dose 800 mg, 400 mg,
200 mg and 100 mg, and placebo tablets in four
different sizes, namely placebo tablet 1, placebo tab-
let 2, placebo tablet 3 and placebo tablet 4. The tab-
lets have been manufactured such that the tablets
mentioned in each column below are identical in
shape and size and all the tablets have been coated
(see Table 2).
The central study pharmacist and an assistant will
have access to the randomization list. They will not be
otherwise involved in the conduct of the study in terms
of seeing or enrolling patients or accessing the patients
during follow-up and handling patient data. The drugs
will prepackage and for each enrolled patient, a set of all
the tablets of various sizes, sufficient for the entire
course of study treatment, in two different, sealed and
numbered envelopes for odd and even doses as per the
randomization list, will be given.
At enrollment, the study staff will explain to the
patient to take the appropriate tablets as per the drug-
dosing table according to the weight of the patient. Refer
to the additional Excel sheet for the details (see
Additional file 2). The respective doses for each
Table 1 Power for the overall population, culture-negative patients and culture-positive patients based on the assumptions above
Total sample size in both groups
(culture-positive/-negative)
All patients (ITT): power for
superiority of azithromycin
Culture-negative patients: power
for superiority of azithromycin
Culture-positive patients: power for
“non-inferiority” of azithromycina
300 (150/150) 80% 89% 96%
300 (100/200) 92% 95% 86%
aProbability that the 95% confidence interval for the effect of azithromycin excludes the possibility that azithromycin is associated with a 1.5-fold slower fever
clearance time (FCT) in culture-positive patients. ITT intention-to-treat
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patient of a particular weight will be identical for
both treatment groups.
Patients in the co-trimoxazole arm will receive both
an odd and an even number of doses of co-trimoxazole
tablets each day. Similarly, patients in the azithromycin
arm will receive an odd number dose of azithromycin
tablets and an even number dose of placebo tablets to
blind disparity of drug frequency each day (see Table 3).
 Odd number dose: doses 1, 3, 5, 7, 9, 11 and 13
 Even number dose: doses 2, 4, 6, 8, 10, 12 and 14
Treatment allocation will be concealed from the pa-
tient, investigators, study physician, study nurse and
other study staffs throughout the study and will hence
be double blinded.
Administration and compliance
The first dose of the study drug will be administered
under direct observation of the study physician in the
hospital. If there is no hypersensitivity reaction, the pa-
tient will be discharged. Patients will be advised to take
medication as per the study protocol and their compli-
ance will be monitored by daily telephone calls and
home visits on days 2 and 4.
To account for the need for re-administration in cases of
vomiting, patients will be additionally given doses 15, 16,
17 and 18. If a patient has vomiting within 30 min of taking
the drug, and if the volume is significant or the tablets are
visible in the vomitus, the dose vomited should be re-
administered from the same pouch. No dose will be re-
administered more than once. If there are more than four
episodes of vomiting after taking drugs, patients will be
asked to visit the hospital and will be considered for discon-
tinuation of the given study drug.
Un-blinding
Un-blinding denotes revealing the identity of the study
treatment. Un-blinding will take place in the event that
the patient wishes to discontinue participation in the
study or when the study physician and attending phys-
ician feel that the study drug needs to be un-blinded due
to drug side effects. Study treatment should only be un-
blinded if knowing the treatment will result in a change
in the patient’s management.
The decision as to whether or not to un-blind should
be discussed with the principal investigator (PI).
Un-blinding will take place in the presence of the
pharmacist and the attending physician. Un-blinding will
be documented in the CRF.
Data collection, management and analysis
Data handling and storage of records
Patient data will be recorded on paper CRFs, and en-
tered on electronic CRFs later on a secure database via
laptop computers, by study physicians and study nurses
and transferred to the Data Management Team. Original
paper study records will be kept for a minimum of
15 years in a secure location.
Data access
The final trial dataset will be accessible to the trial
team in the two collaborating institutions, OUCRU-
Nepal at PAHS and OUCRU-Vietnam. All decisions
on trial data use for analysis will be made by the PI.
The data-entry team, which comprises study nurses
and study physicians, will have access to the database
forms. The IT team at OUCRU-Vietnam will have
access to the database worksheets which they will
provide to the DSMB statistician for interim analysis
and to the study statistical analysis team for the end-
of-study analysis. All electronic data will be kept safe
and securely backed up for at least 15 years after the
end of the study.
Statistical analysis
The primary analysis population for all analyses is the
full analysis population including all randomized
subjects. Patients will be analyzed according to their
randomized arm (intention-to-treat). In addition, the
analyses will be repeated in the subsets of patients with
blood-culture-confirmed enteric fever and in culture-
negative patients.
The primary endpoint, the interval-censored FCT, will
be compared between the two groups based on a
Table 2 Doses formulation for equivalent tablets in two arms
Tablet 1 Tablet 2 Tablet 3 Tablet 4
Azithromycin 800-mg tablet Azithromycin 400-mg tablet Azithromycin 200-mg tablet Azithromycin 100-mg tablet
Placebo tablet 1 Placebo tablet 2 Placebo tablet 3 Placebo tablet 4
Co-trimoxazole 1200-mg tablet Co-trimoxazole 600-mg tablet Co-trimoxazole 300-mg tablet Co-trimoxazole 150-mg tablet
Table 3 Treatment allocations in each arm
Azithromycin arm Co-trimoxazole arm
Odd dose Even dose Odd dose Even dose
Azithromycin tablets Placebo
tablets
Co-trimoxazole
tablet
Co-trimoxazole
tablet
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Weibull accelerated-failure-time model with the treat-
ment arm as the only covariate. The distribution of the
FCT over time in each treatment arm will be further vi-
sualized using the non-parametric maximum likelihood
estimator (NPMLE).
To summarize treatment failures, we will analyze both
the time to treatment failure and the absolute risk of
treatment failure until day 28. The former will be dis-
played with Kaplan-Meier curves and compared between
the two groups with a Cox regression model with
treatment as the only covariate. The Kaplan-Meier
estimate on day 28 will be used as the estimate of the
absolute risk of treatment failure and the comparison
will be based on standard errors according to Green-
wood’s formula.
Predefined subgroup analyses for both FCT and the
time to treatment failure are by culture result (blood
culture-positive or -negative), age (below 14 years or
14 years and older) and by pathogen in culture-
confirmed patients (S. typhi or S. paratyphi A).
If further diagnostic tests, including ELISA and PCR,
for the blood-culture-negative cases identify subsets of
the study population with the same alternative diagnosis,
including at least 15 subjects, outcomes in these subsets
will also be analyzed.
This trial utilizes a pragmatic dosing regimen; that is,
the tablets will be dispensed without breaking and a near
accurate dose will be given in each treatment arm. To
assess the effect of variation in the actual dose, a sub-
group analysis will be conducted by the actual dose that
a patient is given. This is derived from the intended dose
from the patient’s body weight and drug-dosing table
(see Additional file 1). This is a baseline measurement
set at the time of randomization and will be known once
un-blinding is done.
Dissemination policy
We will publish the trial results in Hospital Grand Rounds
and Medical Society meetings in Nepal. We will also use
the Rotary Club and other such venues to disseminate the
findings of the study as a way of public engagement. At
the end of the study, the findings will be published on an
open-access, peer-reviewed medical journal.
Authorship eligibility guidelines
Authorship eligibility will be based on current recom-
mendations of the International Committee of
Medical Journal Editors (ICMJE). We are not using
professional writers.
Monitoring
Data and Safety Monitoring Board (DSMB)
An independent Data and Safety Monitoring Board will
be set up which will consist of qualified volunteers with
the necessary knowledge of clinical trials. The DSMB
will review and approve a monitoring plan before the
study commences. This will include how often the
DSMB should receive summary reports. All data
reviewed by the DSMB will be in the strictest confi-
dence. A DSMB charter will outline its responsibilities
and operational plan. The DSMB will be notified within
7 days of the PI being aware of the occurrence of a
serious unexpected adverse event. An interim analysis to
compare the primary outcomes in the two groups will
be carried out once the data from the day-28 visit is
available from the 100th and 200th patients and the re-
port will be submitted to the DSMB.
The PI will also submit an annual progress report (or
when requested) to the relevant Research Ethic Committees
(Oxford University and Nepal Health Research Council),
host organization and sponsor. In addition, an end-of-study
notification and final report will be submitted to the
same parties.
Risks
Study procedures, including physical examination and
phlebotomy, are standard clinical-care procedures and
carry minimal risks. Phlebotomy may result in bruising,
pain or infection at the site. The volume of blood drawn
from children is below the WHO recommended limits
for research in sick children [25].
The investigators will retain custody of the data and
samples that will be jointly protected by the collaborat-
ing institutions according to established procedures and
security barriers. Any future use of stored samples
carries risk of loss of privacy and possibly stigmatization.
The appropriate ethical committees will evaluate these
and other issues before any testing is performed.
Treatments in both arms are commonly used in this set-
ting with very few complications. Administration of the
first dose of both will be in the hospital setting to reduce
the risk associated with the possibility of allergic reaction.
Side effects of azithromycin
Common: diarrhea, nausea, abdominal pain
Uncommon: palpitations, chest pain, jaundice,
vomiting, dizziness, headache, vertigo, fatigue,
inflammation and allergic reaction, decreased hearing,
blurred vision, dark urine
Side effects of co-trimoxazole
Common: loss of appetite, nausea, vomiting, diarrhea,
reversible exanthemas, headache, fever
Uncommon: severe allergic skin reactions (Stevens-
Johnson syndrome, Lyell’s syndrome, hematological
complications (e.g., agranulocytosis, pancytopenia),
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cholestatic jaundice, pancreatitis, colitis, nephritis,
vasculitis, aseptic meningitis, neuropsychiatric
symptoms
Side effects will be monitored by telephone calls and
the patients will be asked to attend to hospital when
necessary.
Adverse events and reporting
Definitions
An adverse event (AE) is any untoward medical event
that occurs to a study participant during the course of
the study whether or not that event is considered related
to the study drug. An AE can, therefore, be any unfavor-
able and unintended sign, a symptom, or disease (in-
cluding an abnormal laboratory finding) temporarily
associated with the study drug, whether or not
considered related to the study drug. Clinical or
laboratory events are considered AEs only if they
occur after the first dose of study treatment. Stable
chronic conditions, such as arthritis, which are
present prior to clinical trial entry and do not worsen
are not considered AEs and will be documented in
the subject’s clinical chart as medical history.
Serious adverse event (SAE) an AE is considered to
be “serious” if it results in one of the following
outcomes:
 Death
 Life-threatening event (the subject was at immediate
risk of death at the time of the event; it does not
refer to an event which hypothetically might have
caused death if it were more severe)
 Inpatient hospitalization (new admissions) or
prolongation of existing hospitalization (beyond
what is expected for normal clinical care)
 Persistent or significant disability/incapacity (a
substantial disruption of a person’s ability to
conduct normal life functions)
 Congenital anomaly/birth defect
Patients will be followed up until the resolution of
such symptoms even after the study comes to an
end.
Any undiagnosed pregnancy during which treatment
occurred will be followed until outcome. Any con-
genital abnormality or birth defect will be recorded as
a SAE.
Unexpected serious adverse events (USAEs) are unto-
ward medical events which fit one or more of the
criteria for SAEs above and which are not considered a
part of normal clinical progression of disease or an ex-
pected reaction to standard treatment therapy. Any
event that becomes of concern to the investigators or
study physicians during the course of the trial may be
reported as a USAE.
Reporting
All adverse events will be fully recorded in the “Adverse
events page” in the CRF including duration, severity,
outcome and relationship to the study drug. We will
refer to the Common Terminology Criteria for Adverse
Events (CTCAE V4). All adverse events will be noted in
the study based on the Patient-reported Symptom
Questionnaire and by probing questions based on the
AE page of the CRF by the study physician on follow-up
visits on days 7 and 14.
Trial auditing
The trial will undergo both internal and external audit-
ing. Internal auditing will be performed on a day-to-day
basis by study physicians, study nurses and the Clinical
Trial Unit, who will check data details and any discrep-
ancies will be met with follow-up maintenance and
appropriateness of patient recruitment. External auditing
will be carried out by the Clinical Trials Unit at our
collaborating research unit, OUCRU-VN, twice a year
with reassessment of all study documents and CRFs and
a review of crucial trial events.
Discussion
There have been several published studies that used
azithromycin or co-trimoxazole for the treatment of en-
teric fever, but there have been no head-to-head compari-
sons of the two drugs for UFI [5–7, 14, 15]. The studies
that have used co-trimoxazole have generally been of
small sample size and have not included all UFIs [14, 15].
Azithromycin is recommended for the treatment of
the rickettsial fevers but its usefulness for UFI treatment
in settings where rickettsial infections and enteric fever
are common needs to be assessed [26]. There have been
no trials performed for the treatment of UFI in our set-
ting of fluoroquinolone-resistant enteric fever.
There have been attempts to develop protocols for the
initial investigations and management of UFIs in South
Asia [27], but the choice of antimicrobial in such proto-
cols is still empirical and guided by subjective judgment.
This study should pave the way for defining antibiotic
guidelines for such presentations in Nepal.
The findings of this study will be important for clinicians
as it will help them choose the best empirical treatment for
UFI and reduce the rates of treatment failures and the risk
of complications, and thus directly reduce patient suffering.
This will also avert the need of using multiple antimicro-
bials to treat a common presentation of illness in Nepal
and South Asia and thus may prevent the overuse of
antimicrobials especially in the treatment of UFI.
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This paper outlines the study protocol following the
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) guidelines for intervention
trials (the SPIRIT Checklist is included as Additional file 3)
Trial status
The trial is currently ongoing. It started enrollment in
June 2016 and aims to be completed in June 2019. At
the time of acceptance of this manuscript for publica-
tion, 90 participants (27% of the estimated sample size)
have been enrolled into the study.
Additional files
Additional file 1: Drug-dosing table. Calculation of drug dose according
to the patients’ weight in each arm. (XLSX 21 kb)
Additional file 2: Simplified drug-dosing table. A simplified drug-dosing
table derived from a drug-dosing table which explains the number of
tablets required for each kilogram weight of the patient irrespective of
the treatment arm. (XLSX 9 kb)
Additional file 3: SPIRIT Checklist. A checklist according to Standard
Protocol Items: Recommendations for Interventional Trials (SPIRIT)
guidelines. (DOCX 52 kb)
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